The CNPV pilot program, which debuted in June 2025, aims to accelerate FDA decisions from the typical 10- to 12-month timeline to as little as one to two months for selected products that address critical public health needs, such as innovative therapies for widespread diseases or unmet medical needs
any insulin adjustments must be clinician-led
During this shortage period, federal law allowed compounding pharmacies to mass-produce copies of GLP-1 drugs to meet demand
IGFI, IGFBP3 and breast cancer risk in women: the European Prospective Investigation into Cancer and Nutrition (EPIC)
Nucleic Acids Res 46:W486W494 Correale J (2021) Immunosuppressive amino-acid catabolizing enzymes in multiple sclerosis Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Consequently, when this immunometabolism occurs with antigen from melanocytes, immune self-tolerance is lost, and melanocytes apoptosis occurs via accessory pathway activation